Gilead plays a central role in developing single tablet regimens – with one pill once a day, patients can take all of their medication in each dose.
Our liver disease programs focus on expanding treatment options for chronic hepatitis B and C.
Our scientists are applying new knowledge about how cancers grow and spread to potentially enhance and improve cancer therapy.
Our medicines aim to help patients with cardiovascular disease return to their daily activities, and we are exploring potential new indications.
We research and develop treatments for serious respiratory conditions such as influenza, cystic fibrosis and other diseases of the lungs.
Gilead medicines treat severe fungal and parasitic infections, and address vision loss caused by degenerative eye diseases.
Gilead has made it a priority to help ensure worldwide access to its first-in-class treatment for hepatitis C. Learn more.
Our greatest asset is our employees – not only their individual skills and expertise, but their personal commitment to our mission of making a difference in the lives of patients.
October 16, 2014
Health Canada Issues Notice of Compliance for Gilead’s Harvoni™ (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C